Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Clear Cell Renal Carcinoma (Ccrcc)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 0 results

Early research (Phase 1)Active Not RecruitingNCT05277051
What this trial is testing

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Who this might be right for
Neoplasms
GlaxoSmithKline 152
Testing effectiveness (Phase 2)Looking for participantsNCT07188896
What this trial is testing

Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Who this might be right for
Advanced Renal Cell Carcinoma (aRCC)Metastatic Renal Cell Carcinoma ( mRCC)Clear Cell Renal Cell Carcinoma (ccRCC)
Brian Rini 120
Early research (Phase 1)Ended earlyNCT06191796
What this trial is testing

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Who this might be right for
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Exelixis 25
Early research (Phase 1)Ended earlyNCT05121948
What this trial is testing

HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Who this might be right for
Squamous Cell Carcinoma of Head and NeckColo-rectal CancerNon Small Cell Lung Cancer+3 more
HiberCell, Inc. 35
Testing effectiveness (Phase 2)Study completedNCT00142415
What this trial is testing

Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer

Who this might be right for
Metastatic Renal Cell Carcinoma
Ludwig Institute for Cancer Research 26